Piper Sandler analyst Christopher J. Raymond reiterated an Overweight rating and $66.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN)The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE